Work

Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.5_suppl.49

Authors: David S. Hong, Aparna Parikh, Geoffrey Shapiro, Andrea Varga, Aung Naing, Funda Meric-Bernstam, Larisa Reyderman, Xingfeng Bao, Terri A. Binder, Min Ren, Amy Siu, Lu Xu, Mingjie Liu, Satish Dayal, Vijay Bhagawati-Prasad, Ilian Tchakov, Takashi Owa, Chean Eng Ooi, Aurelien Marabelle

Institutions: The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Institut Gustave Roussy, Eisai (United States), Eisai (United Kingdom)

Language: English

Topic: Inflammatory mediators and NSAID effects

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2792267647

Cites:

Cited by: 3

Related to: 10